News

News

PublISHED ON 19 May 2020

UpDATED ON 20 May 2020

Sweden participates in clinical WHO study

Sweden is participating in a major clinical study conducted by WHO, aimed at testing a number of antiviral medicines on patients around the world who are being treated for COVID-19.

Because more than 100 countries are taking part in the WHO study Solidarity Trial, the patient base is large. This makes it quicker to see whether any of the preparations are effective, and can begin to be used to treat the disease.

The Swedish Government recently appointed Soo Aleman, Consultant Physician at the Karolinska University Hospital and Associate Professor at Karolinska Institutet, to be the national coordinator for the Swedish part of the study. The Swedish Research Council will fund Swedish participation, as soon as the investment is formalized in the regulatory letter.

“It is important for Sweden to be part of the international study. Patients in Sweden who have suffered severe COVID-19 can now get access to potentially effective medicines. In the long term we will obtain greater knowledge of what is effective, which will also benefit patients who are not part of the study,” says Jan-Ingvar Jönsson, Secretary General of the Scientific Council for Medicine and Health and Clinical Therapy Research at the Swedish Research Council.

About the studie Solidarity trial on WHO´s websiteexternal link

PUBLISHED ON 19 May 2020

UpDATED ON 20 May 2020

MORE WITHIN THE SAME SUBJECT AREA

  1. 100 million SEK for follow-up studies of COVID-19 vaccines

    Six research environments will share a total of 100 million SEK for follow-up studies of COVID-19 vaccines. The research environments are based on collaborations between different regions, and will focus on different aspects of health and medical car...

  2. MH-D2: Nervous system diseases and psychiatry